IL318052A - Treatment of aiha with baff or baff receptor inhibitory antibodies - Google Patents

Treatment of aiha with baff or baff receptor inhibitory antibodies

Info

Publication number
IL318052A
IL318052A IL318052A IL31805224A IL318052A IL 318052 A IL318052 A IL 318052A IL 318052 A IL318052 A IL 318052A IL 31805224 A IL31805224 A IL 31805224A IL 318052 A IL318052 A IL 318052A
Authority
IL
Israel
Prior art keywords
baff
aiha
treatment
inhibitory antibodies
receptor inhibitory
Prior art date
Application number
IL318052A
Other languages
Hebrew (he)
Inventor
Vladimir Bezlyak
Tomasz Lawniczek
Emerenziana Marturano
Miona Stankovic
Patrick Urban
Original Assignee
Novartis Ag
Vladimir Bezlyak
Tomasz Lawniczek
Emerenziana Marturano
Miona Stankovic
Patrick Urban
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Vladimir Bezlyak, Tomasz Lawniczek, Emerenziana Marturano, Miona Stankovic, Patrick Urban filed Critical Novartis Ag
Publication of IL318052A publication Critical patent/IL318052A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL318052A 2022-07-19 2023-07-17 Treatment of aiha with baff or baff receptor inhibitory antibodies IL318052A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263368825P 2022-07-19 2022-07-19
US202263384051P 2022-11-16 2022-11-16
PCT/IB2023/057257 WO2024018350A1 (en) 2022-07-19 2023-07-17 Treatment of aiha with baff or baff receptor inhibitory antibodies

Publications (1)

Publication Number Publication Date
IL318052A true IL318052A (en) 2025-02-01

Family

ID=87556046

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318052A IL318052A (en) 2022-07-19 2023-07-17 Treatment of aiha with baff or baff receptor inhibitory antibodies

Country Status (9)

Country Link
US (1) US20260139065A1 (en)
EP (1) EP4558522A1 (en)
JP (1) JP2025523874A (en)
KR (1) KR20250040011A (en)
CN (1) CN119546641A (en)
CA (1) CA3261672A1 (en)
IL (1) IL318052A (en)
TW (1) TW202404639A (en)
WO (1) WO2024018350A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026064677A2 (en) * 2024-09-20 2026-03-26 Paragon Therapeutics, Inc. Baff receptor-binding polypeptides, compositions, and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
JP2022515152A (en) * 2018-12-19 2022-02-17 シティ・オブ・ホープ BAFF-R bispecific T cell engager antibody

Also Published As

Publication number Publication date
US20260139065A1 (en) 2026-05-21
TW202404639A (en) 2024-02-01
WO2024018350A1 (en) 2024-01-25
CA3261672A1 (en) 2024-01-25
CN119546641A (en) 2025-02-28
JP2025523874A (en) 2025-07-25
KR20250040011A (en) 2025-03-21
EP4558522A1 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
SG11202010472XA (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
IL288590A (en) Automatic prediction of blood infections
LT3768304T (en) COMPOSITIONS AND METHODS FOR ENHANCING OR ENHANCED TRANSDUCTION OF GENE THERAPY VECTORS AND REMOVING OR REDUCING IMMUNOGLOBULINS
IL288523A (en) Compounds for treatment of pd-l1 diseases
IL291665A (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease
MA53664A (en) COMPOUNDS FOR THE TREATMENT OF CERTAIN LEUKEMIA
IL287904B2 (en) Combination treatment of arthritic disease
IL291687A (en) Methods for treating myelofibrosis and related conditions
EP3773632A4 (en) METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMAS
MA55218A (en) ESKETAMINE FOR THE TREATMENT OF DEPRESSION
EP3504204A4 (en) INDAZOLYL-L, 2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR THE INHIBITION OF RHO ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE
EP3968989A4 (en) COMPOUND FOR THE TREATMENT OF GOUT OR HYPERURICAEMIA
IL287264A (en) Compounds and methods for the treatment of ocular disorders
HUE057197T2 (en) Process for the adjuvant treatment of naphtha
EP3993787A4 (en) ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF MUTANTS
CA3261672A1 (en) Treatment of aiha with baff or baff receptor inhibitory antibodies
HUE070524T2 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
EP3985031C0 (en) BETA GLUCAN FOR THE TREATMENT OF THROMBOCYTOPENI
IL327070A (en) Methods for the treatment of cardiovascular disease
MA56179A (en) TREATMENT OF SYNUCLEINOPATHIES
PT3781210T (en) Treatment of sepsis and septic shock
EP3950707A4 (en) Composition comprising albumin-coupled slit3 lrrd2 for prevention or treatment of muscle disease
EP3934649A4 (en) METHODS OF TREATING A DISEASE WITH LEVOKETOCONAZOLE
MA53914A (en) CRYSTALLINE POLYMORPHS OF BRUTON'S TYROSINE KINASE INHIBITORS
GB201911728D0 (en) Bacterial composistions for the treatment of disease